Entyvio, Remicade effective in checkpoint inhibitor-induced enterocolitis

Remicade and Entyvio were effective for the treatment of patients with checkpoint inhibitor-induced enterocolitis, according to the results of a meta-analysis.Nick Powell, of the division of digestive diseases at Imperial College London, and colleagues wrote the success of checkpoint inhibitors in cancer treatment comes with the downside of immune-mediate toxicity. Current therapy includes corticosteroids and Remicade (infliximab, Janssen).“Checkpoint inhibitor-induced enterocolitis is one of the most serious immune-mediated complications and is especially common in combinationRead More

Share on facebook
Share on twitter
Share on linkedin